Invest Securities this morning confirmed its Buy rating on TME Pharma shares, with an unchanged target price of 4.2 euros.

This recommendation comes as the company this morning published median overall survival data at 15 months from its expansion study in glioblastoma evaluating the NOX-A12/radiotherapy/bevacizumab tricombination.

At this stage, 5 out of 6 patients in the cohort are still alive, compared with known data for the same patient profile showing a median overall survival of 9.7 months with standard of care treatments. Although based on a small cohort, these results are extremely promising", emphasizes Invest.

The broker indicates that, depending on future data and ongoing discussions with the FDA, a Ph II PoC study could be launched in the near future, with the potential to pave the way for accelerated approval.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.